



**HAL**  
open science

## **Intensive care readmissions in the first year after lung transplantation: Incidence, early risk factors and outcome**

Enora Atchade, Malek Younsi, Yoann Elmaleh, Alexy Tran-Dinh, Sylvain Jean-Baptiste, Sébastien Tanaka, Parvine Tashk, Aurélie Snauwaert, Brice Lortat-Jacob, Lise Morer, et al.

### ► To cite this version:

Enora Atchade, Malek Younsi, Yoann Elmaleh, Alexy Tran-Dinh, Sylvain Jean-Baptiste, et al.. Intensive care readmissions in the first year after lung transplantation: Incidence, early risk factors and outcome. *Anaesthesia Critical Care & Pain Medicine*, 2021, 40 (6), 10.1016/j.accpm.2021.100948 . hal-04540129

**HAL Id: hal-04540129**

**<https://hal.univ-reunion.fr/hal-04540129v1>**

Submitted on 22 Jul 2024

**HAL** is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.



Distributed under a Creative Commons Attribution - NonCommercial 4.0 International License

## **Intensive care readmissions in the first year after lung transplantation:**

### **Incidence, early risk factors and outcome**

Enora ATCHADE<sup>1\*</sup>, Malek YOUNSI<sup>1</sup>, Yoann ELMALEH<sup>1</sup>, Alexy TRAN-DINH<sup>1,2</sup>, Sylvain JEAN-BAPTISTE<sup>1</sup>, Sébastien TANAKA<sup>1,3</sup>, Parvine TASHK<sup>1</sup>, Aurélie SNAUWAERT<sup>1</sup>, Brice LORTAT-JACOB<sup>1</sup>, Lise MORER<sup>4</sup>, Arnaud ROUSSEL<sup>5</sup>, Yves CASTIER<sup>5,6,7</sup>, Hervé MAL<sup>4,6,7</sup>, Chris DE TYMOWSKI<sup>1,6,8</sup>, Philippe MONTRAVERS<sup>1,6,7</sup>

1. APHP, CHU Bichat-Claude Bernard, DMU PARABOL, 46, rue Henri Huchard, 75018 Paris, France
2. INSERM U1148, LVTS, CHU Bichat-Claude Bernard, 46, rue Henri Huchard, 75018 Paris, France
3. INSERM UMR 1188 Diabète Athérombose Université de la Réunion, Réunion Océan Indien, (DÉTROIT), Saint Denis de la Réunion, France
4. APHP, CHU Bichat-Claude Bernard, Service de Pneumologie B et Transplantation Pulmonaire, 46, rue Henri Huchard, 75018 Paris, France
5. APHP, CHU Bichat-Claude Bernard, Service de Chirurgie Vasculaire, Thoracique et Transplantation, 46, rue Henri Huchard, 75018 Paris, France
6. Université de Paris, UFR Paris Diderot, Paris, France
7. INSERM UMR 1152, ANR-10-LBX-17; Paris, France
8. INSERM U1149, Immunorécepteur et Immunopathologie rénale, CHU Bichat-Claude Bernard, 46, rue Henri Huchard, 75018 Paris, France

**\*Corresponding author:** Enora Atchade

Réanimation Chirurgicale, Hôpital Bichat Claude Bernard, 46, rue Henri Huchard, 75018 Paris, France

**Email:** [enora.atchade@aphp.fr](mailto:enora.atchade@aphp.fr)

**Keywords:** Lung transplantation; ICU readmissions; Early associated factors; Outcome

**Abbreviations:**

AKI: acute kidney injury

ARF: acute respiratory failure

BMI: body mass index

COPD: chronic obstructive pulmonary disease

ECMO: extra corporeal membrane oxygenation

HBP: high blood pressure

ICU: intensive care unit

IPF: idiopathic pulmonary fibrosis

LT: lung transplantation

MV: mechanical ventilation

NBA: neuromuscular blocking agents

NIV: non-invasive ventilation

PGD: primary graft dysfunction

PRC: packed red cell

RRT: renal replacement therapy

SAPS II: Simplified Acute Physiology Score II

SOFA: sequential organ failure assessment

**Acknowledgment:** None

**Funding:** None

**Availability of data and materials:** Data are available on request to the corresponding author

### **Authors' contribution**

EA participated in the study design, acquisition of data, analysis and interpretation of data, performed the statistical analysis and drafted the manuscript. MY participated in the acquisition, analysis and interpretation of data. ATD, SJB, ST, PT, AS, BLJ, LM, AR, YC and HM made substantial contributions to the interpretation of data. CDT and PM were involved in the study design, statistical analysis, interpretation of data and drafted the manuscript. All authors have read and approved the final manuscript.

### **Ethics and consent to participate**

The study was approved by the Paris North Hospitals Institutional Review Board (Paris VII University, AP-HP, IRB No 0006477). According to French law, after information was collected, the absence of refusal was obtained from all patients.

**Consent for publication:** Not applicable

**Competing interests:** There are no competing interests related to the publication of this manuscript

## **ABSTRACT**

### **BACKGROUND**

Predictive factors of intensive care readmissions after lung transplantation (LT) have not been established. The main objective of this study was to assess early risk factors for ICU readmission during the first year after LT.

### **METHODS**

This retrospective, observational, single-centre study included all consecutive patients who underwent LT in our institution between January 2016 and November 2019. Patients who died during the initial hospitalisation in the ICU were excluded. Surgical and medical ICU readmissions were collected during the first year. The results are expressed as medians, interquartile ranges, absolute numbers and percentages. Statistical analyses were performed using the chi-square test, Fisher's exact test and Mann-Whitney U test as appropriate ( $p < 0.05$  as significance). Multivariate analysis was performed to identify independent risk factors for readmission. The Paris-North-Hospitals Institutional Review Board reviewed and approved the study.

### **RESULTS**

A total of 156 patients were analysed. Eighteen of them (12%) died during the initial ICU hospitalisation. During the first year after LT, ICU readmission was observed for 49/138 (36%) patients. Among these patients, 14/49 (29%) died during the study period. Readmission was

mainly related to respiratory failure (35 (71%) patients), infectious diseases (28 (57%) patients), airway complications (11 (22%) patients), and immunologic complications (4 (8%) patients). In the multivariate analysis, ICU readmission was associated with the use of high doses of catecholamines during surgery, and the increased duration of initial ICU stay.

## **CONCLUSION**

The initial severity of haemodynamic failure and a prolonged postoperative course seem to be key determinants of ICU readmissions after LT.

## BACKGROUND

Despite an improved survival rate reported in the most recent cohorts (1), lung transplant recipients are frequently exposed to serious medical complications requiring hospital readmission. Few studies have addressed this issue, most of them are based on a retrospective analysis (2–10). According to previous studies, hospital readmissions after lung transplantation (LT) are mainly related to pulmonary complications (59%), followed by gastrointestinal (18%), cardiac (5%), metabolic (2.5%) and neurologic complications (2.5%) (6,11). Reintubation, male sex, high lung allocation score, bronchopulmonary fistula, and body surface area have been identified as risk factors for hospital readmissions (8).

Studies assessing ICU readmissions after LT are limited, focusing on incidence, reasons for ICU readmission and risk factors for mortality. In these studies, ICU readmissions were first related to sepsis and acute respiratory failure (ARF) (3–5,12). The mortality rate following ICU readmission is high and estimated to be between 25 and 62.5% (3,4,12), with 20 to 40% of these cases related to sepsis. Interestingly, early risk factors for ICU readmission during the first year after LT have not already been assessed.

The main objective of this study was to assess early risk factors for readmission in the ICU during the first year after LT. The secondary aims were to study the incidence, reasons for readmission, characteristics of the second ICU stay and outcomes of these ICU-readmitted patients.

## **METHODS**

### ***Study population***

All consecutive patients who underwent LT at Bichat Claude Bernard Hospital, Paris, from January 2016 to November 2019 were prospectively included in this observational, single-centre study and retrospectively analysed. Patients who died during the initial hospitalisation in the ICU after the LT procedure were excluded from the analysis. Before inclusion in the study, the patient's absence of refusal was obtained, according to French law. The Paris-North-Hospitals Institutional Review Board (Paris Diderot University, APHP, IRB No. 0006477) reviewed and approved the study.

### ***Perioperative management***

Perioperative care was standardised for all patients (13–15) according to current practices (16). After the surgical procedure, patients were admitted to the surgical ICU.

### ***Data collection***

On ICU admission, demographic characteristics, underlying diseases, clinical data, and severity score (SOFA score on admission) were prospectively recorded. Characteristics of the intraoperative period (type of procedure, need for extracorporeal membrane oxygenation (ECMO), catecholamine administration and dose, fluid administration, intraoperative transfusion) were recorded. High doses of catecholamine



were defined as administration of norepinephrine or epinephrine  $> 0.5 \mu\text{g}/\text{kg}/\text{min}$ . Postoperative complications during the initial ICU hospitalisation following LT were recorded (multiple organ dysfunction syndrome defined as development of two or more organ dysfunction, prolonged ECMO support, primary graft dysfunction (PGD) defined according to ISHLT revised definition (17), acute kidney injury (AKI) defined according to KDIGO criteria (18), acute rejection, infectious complications, respiratory status, thoracic reintervention, abdominal surgery). Medical and surgical ICU readmissions, to our institution and others, were collected in the pneumology medical record of all LT recipients during the first year. Reasons for readmission, hospital discharge before ICU readmission, characteristics of the second ICU hospitalisation (organ failure, need for mechanical ventilation (MV), catecholamines, renal replacement therapy (RRT), ECMO), and outcome (death within the first year after LT) were also collected in the medical records of recipients.

### ***Statistical analysis***

Qualitative data are expressed as absolute numbers and proportions, and quantitative data are expressed as medians and interquartile ranges. Statistical analysis was performed using the chi-square test or Fisher's exact test for qualitative data and Mann-Whitney or Kruskal-Wallis tests for quantitative data, as appropriate. The level of statistical significance was set at 5%. Multivariate associations were computed with binary logistic regression models. The variables with nominal 2-tailed  $p$  value less than 0.2 were entered into a backward stepwise selection method. When similar variables were associated with ICU readmission, the variable with the highest clinical relevance was included in

the multivariate analysis. The one-year survival rate was analysed by the Kaplan-Meier test and compared by a log rank test. RCore Team (2013) was used for statistical analysis (R Foundation for Statistical Computing, Vienna, Austria, <http://www.R-project.org/>).

## RESULTS

### *Characteristics of the study population*

Between January 2016 and November 2019, 156 patients underwent LT in our institution. Eighteen (12%) of them died during hospitalisation in the ICU after the surgical procedure and were excluded from the analysis. The flow chart of the study is presented in **Figure 1**. Most of the patients were male and underwent bilateral LT, mainly for primary pulmonary fibrosis and COPD, while cystic fibrosis was the indication for LT in one patient. The characteristics of the study population are presented in Table 1. ICU readmission was observed in 49/138 (35%) patients in the first year after LT. Clinical characteristics are presented in **Table 1**, and delay for readmission is presented in **Figure 2**.

### *Reasons for ICU readmission and characteristics of the second ICU stay*

Reasons for ICU readmission and characteristics of the second ICU stay are presented in **Table 2**. Among the ICU-readmitted patients, 19 (39%) had been discharged from the hospital after initial hospitalisation, while 30 (61%) were still hospitalised and readmitted to the ICU. The characteristics and outcomes of ICU-readmitted patients depending on hospital discharge before readmission are presented in **Table 3**.

### *Outcome of patients with and without readmission in ICU*

One-year survival depending on ICU readmission is presented in **Figure 3**. The characteristics of the second ICU stay depending on survival status are presented in **Table 2**. Among the 89 non-readmitted patients, 6 (7%) died in the first year after LT. Among ICU-readmitted patients,

14/49 (29%) died during the first year after LT, 7 of them (50%) died due to *Pseudomonas aeruginosa* pneumonia, 3 of them died because of a bronchopleural fistula, and the others died because of multifactorial aetiologies; 8/14 (57%) patients died after a withdrawing or withholding treatment decision. During the second ICU hospitalisation, the need for ECMO, catecholamine support and MV were significantly associated with death during the first year after LT.

### ***Risk factors for early ICU readmission***

Risk factors for early ICU readmission are presented in **Table 1**. None of the preoperative characteristics of LT recipients (demographic data, underlying diseases, comorbidities) were significantly associated with ICU readmission. In the multivariate analysis, the use of high doses of catecholamines during surgery, and an increased duration of ICU stay were independent risk factors for ICU readmission during the first year after LT. The median delay for ICU readmission was not different between the patients receiving high doses of catecholamines during surgery (readmission after 91 [26-155] days) and those without this support (readmission after 134 [36-208] days,  $p = 0.094$ ).

### ***Risk factors for death at one year***

The risk factors for death at one year in the multivariate analysis are presented in **Table 4**.

## DISCUSSION

In this single-centre retrospective cohort analysing all consecutive patients who underwent LT, one-third of the recipients were readmitted in the ICU in the first year after transplantation. Among them, 61% were still hospitalised at the time of ICU readmission. Readmission was mainly related to respiratory failure, infectious diseases, airway and immunologic complications. The risk factors for ICU readmission in the multivariate analysis were the administration of high doses of catecholamines during surgery, and an increased duration of initial ICU stay. The one-year mortality rate of readmitted patients was 29%.

Despite an improvement in median survival after LT reported in the most recent cohorts (1), which reached 6.7 years, medical and surgical complications requiring hospital readmission frequently occurred during the first year after LT (1,8,19). Although the risk factors for hospital readmission have been identified, risk factors for ICU readmissions have not been as thoroughly explored. Prior studies have focused on reasons for ICU readmissions and risk factors for mortality (3,7,8). To our knowledge, early predictive factors of ICU readmission during the first year after LT have not yet been established.

None of the assessed preoperative characteristics (demographic data, underlying disease and comorbidities) showed an association with ICU readmission during the first year after LT, which is consistent with prior studies (8,11). The diagnosis leading to LT was not identified as a risk

factor for ICU readmission. In our cohort, the characteristics of the initial ICU stay were not significantly different for IPF and COPD patients. In addition, the median number of pneumonias and their duration of ICU stay were not different for these two subgroups of patients.

The only intraoperative risk factor identified on multivariate analysis was the administration of high doses catecholamines during surgery. This association has not yet been identified and could reflect the increased severity of these patients. Clinical severity scores were identified as risk factors for ICU readmissions in general ICU populations (20–22). In univariate analysis, the use of ECMO support during surgery was associated with ICU readmissions during the first year after LT. However, this association was not identified in the multivariate analysis, limiting the value of this observation. Interestingly, the large postoperative use of ECMO was not a discriminative factor. Finally, the prolonged use of this technique was too rare to become a risk factor for readmission.

In the postoperative period, the multivariate analysis identified the duration of the initial ICU stay as an independent risk factor for readmission. In the general population, prolonged ICU stay is a known risk factor for ICU readmission (20,21). We can formulate several hypotheses to explain why this assumption is also valid for ICU readmissions of LT recipients. A longer initial ICU stay reflects higher rates of postoperative complications (duration of haemodynamic failure, number of pneumonia or occurrence of septic shock), with a negative impact on the general condition of the recipients (sarcopenia, ICU-acquired neuromyopathy). ICU-induced deconditioning of LT recipients makes them vulnerable to subsequent complications leading to ICU readmission.

Previous studies identified reintubation, male gender, high lung allocation score, bronchopulmonary fistula, and body surface area as risk factors for hospital readmissions (8). In our cohort, none of the assessed factors (male gender, BMI, reintubation) was identified as risk factor of ICU readmission. The difference in the risk factors for hospital and ICU readmissions can be explained by the low proportion of ICU readmissions among all the hospital readmissions, with different causes of readmissions. The relatively small size of our cohort could also explain the lack of detection of some risk factors.

Previous studies identified sepsis and ARF as the main reasons for ICU readmission after LT (3,4,12). Comparable results were obtained in our study, with a high predominance of ARF (71%), as well as infectious diseases (57%), with a predominance of pneumonia and pleuropneumonia. *Pseudomonas aeruginosa* was responsible for half of all infectious diseases. Airway complications (obstructive ischaemic bronchitis, bronchial stenosis, fistulas) were the third indication for ICU readmission in our study. Airway complications were also a significant risk factor for hospital readmissions in the Mollberg et al. study (6).

In our study, ICU readmission was associated with a high mortality rate. Earlier studies have reported similar mortality rates, estimated between 25 and 62.5% (3,5,12,23), including 20 to 40% that are linked to sepsis (23). These variable results are probably related to differences

in the studied cohorts (pathology leading to LT, immunosuppression protocols, microbiological ecology). In the cohort published by Cohen et al., chronic rejection, sepsis and SOFA score on readmission were associated with mortality (5). Interestingly, in our study, a higher mortality rate was observed in ICU-readmitted patients with airway complications. This variable had not been assessed in previous studies. Other factors linked to mortality were the need for MV or catecholamine support after ICU readmission, which have already been described (5,23). These elements must be considered severity markers rather than the cause of death.

The timing of readmission (during initial hospitalisation *versus* after hospital discharge) showed no difference on admission (severity scores, organ failure) or prognosis at one year in our study. Readmissions for infectious disease were much more frequent after hospital discharge. The very small sample size of each group limits the interpretation of these results.

Our study has several limitations; its monocentric design and the relatively small sample size of the cohort limit the extrapolation of our findings. The major representation of IPF and COPD in our cohort and the low number of LTs for cystic fibrosis (15.4% of the procedures worldwide, a single patient in our study) represent a bias in the analysis of the outcome of our cases. This discrepancy could also explain the high mortality rate at one year observed in our cohort compared to international studies (1). However, we assume that our observations could provide valuable information to the reader and help clinicians identify patients who may be at risk of having a poor prognosis.



## **CONCLUSION**

In this retrospective cohort, ICU readmission during the first year after LT was frequent and associated with a higher risk of mortality. Preoperative and intraoperative factors play only a limited role in early ICU readmissions, except for high operative doses of catecholamines. The initial postoperative course in the ICU is of major relevance in these readmissions during the first year after LT. The deleterious value of increased ICU stay might reflect further postoperative complications with a negative impact on the general condition of the recipients. During the second ICU stay, the need for catecholamine, MV or ECMO support seems to be predictive factors of mortality.

**Table 1:** Perioperative demographic characteristics of lung transplant recipients and identified risk factors for ICU readmission by multivariate analysis

				Univariate analysis	Multivariate analysis		
	All patients N = 138 <sup>1</sup>	ICU readmission N = 49 (36) <sup>1</sup>	No ICU readmission	P value <sup>2</sup>	OR	95% CI	P value
<b>Preoperative variables</b>							
Age, years	49 [35-58]	48 [36-62]	49 [32-56]	0.78	-	-	-
Male sex	89 (64)	35 (71)	54 (61)	0.21	-	-	-
Diagnosis leading to LT							
▪ Pulmonary fibrosis	54 (39)	21 (43)	33 (37)	0.51	-	-	-
▪ COPD	51 (37)	18 (37)	33 (37)	0.97	-	-	-
HBP	29 (21)	10 (20)	19 (21)	0.90	-	-	-
Pulmonary hypertension	70 (52)	22 (47)	48 (55)	0.39	-	-	-
Diabetes mellitus	11 (8)	5 (10)	6 (7)	0.52	-	-	-
Dyslipidaemia	36 (26)	14 (29)	22 (25)	0.62	-	-	-
BMI > 29.9 kg·m <sup>-2</sup>	15 (4)	5 (10)	10 (11)	0.85	-	-	-
MV before surgery	6 (4)	2 (2)	4 (8)	0.19	-	-	-
ECMO before surgery	8 (6)	6 (7)	2 (4)	0.71	-	-	-
Retransplantation	2 (1)	1 (1)	1 (2)	1	-	-	-
High emergency LT	22 (16)	13 (15)	9 (18)	0.56	-	-	-
<b>Intraoperative variables</b>							
Bilateral LT	93 (67)	33 (67)	60 (67)	0.99	-	-	-
Epidural anaesthesia	82 (59)	22 (45)	60 (67)	0.01	-	-	-

Haemodynamic support by ECMO	99 (72)	41 (84)	58 (65)	0.021	2.08		0.82-5.68	0.13
Intraoperative catecholamine administration	132 (96)	48 (98)	84 (94)	0.42	-		-	-
Norepinephrine or epinephrine > 0.5 µg/kg/min	43 (31)	25 (51)	18 (20)	< 0.001	4.07		1.83-9.29	< 0.001
Fluid administration > 30 mL/kg	118 (87)	44 (90)	74 (85)	0.43		-	-	-
Red blood cell transfusion	84 (62)	32 (65)	52 (60)	0.52		-	-	-
Transfusion > 5 PRC	20 (14)	12 (13)	8 (16)	0.65		-	-	-
Fresh frozen plasma transfusion	76 (55)	29 (59)	47 (53)	0.47		-	-	-
Platelet transfusion	30 (22)	10 (20)	20 (22)	0.78		-	-	-

### Postoperative variables (ICU stay)

SOFA on admission in ICU	6 [5-8]	6 [5-7]	6 [5-8]	0.77		-	-	-
SAPS II on admission in ICU	36 [25-47]	37 [25-49]	36 [25-46]	0.37		-	-	-
Lactate on ICU admission > 3 mmol/L	31 (22)	14 (29)	17 (19)	0.20		-	-	-
Multiple organ dysfunction during ICU stay	26 (19)	14 (29)	12 (13)	0.026		-	-	-
Catecholamine administration > 3 days	40 (29)	20 (42)	20 (22)	0.018		-	-	-
Duration of catecholamine administration, days	1 [1-3]	2 [1-3]	1 [1-2]	0.045		-	-	-
Postoperative ECMO support	33 (30)	12 (27)	21 (32)	0.61		-	-	-
Duration of ECMO support > 2 days	7 (6)	3 (7)	4 (6)	1		-	-	-
Atrial fibrillation during ICU hospitalisation	39 (28)	16 (33)	23 (26)	0.35		-	-	-
NBA administration	30 (22)	15 (31)	15 (17)	0.061		-	-	-
Prone positioning	12 (9)	7 (14)	5 (6)	0.11		-	-	-
Duration of MV, days	2 [1-5]	3 [1-6]	2 [1-5]	0.12		-	-	-
Reintubation	17 (12)	6 (12)	11 (12)	1		-	-	-
Tracheostomy for ventilation weaning	22 (16)	13 (27)	9 (10)	0.012		-	-	-
PGD	70 (51)	30 (61)	40 (45)	0.067		-	-	-
Septic shock during ICU stay	22 (16)	12 (24)	10 (11)	0.042		-	-	-
Number of pneumonia cases	1 [1-2]	1 [1-2]	1 [1-1]	0.004		-	-	-
Thoracic reintervention	16 (12)	11 (22)	5 (6)	0.003		-	-	-
Abdominal surgery during ICU stay	11 (8)	5 (10)	6 (7)	0.52		-	-	-
AKI	76 (55)	27 (55)	49 (55)	1		-	-	-
RRT	6 (4)	2 (4)	4 (5)	1		-	-	-
Acute antibody-mediated rejection	36 (26)	16 (33)	20 (22)	0.19		-	-	-

Acute cellular rejection	18 (13)	6 (12)	12 (13)	0.84	-	-	-
Duration of ICU stay, days	14 [9-23]	20 [11-29]	13 [9-20]	0.006	1.03	1.01-1.06	0.007

Continuous variables are expressed as median and interquartile range (IQR) and were compared using the Mann-Whitney U test. Categorical variables are expressed as n (%) and were compared with Fisher's exact test. LT: lung transplantation; COPD: chronic obstructive pulmonary disease; HBP: High blood pressure; ECMO: Extra-Corporeal Membrane Oxygenation; BMI Body mass index; PRC: Packed Red Cell; SOFA: sequential organ failure assessment; SAPS: simplified acute physiology score; MV: mechanical ventilation; PGD: Primary graft dysfunction; NBA: neuromuscular blocking agent; AKI: acute kidney injury; RRT : renal replacement therapy

<sup>1</sup> n (%); Median [IQR]

<sup>2</sup> Wilcoxon rank sum test; Pearson's Chi-square test; Fisher's exact test

**Table 2:** Characteristics of the second ICU stay

	All patients readmitted N = 49 <sup>1</sup>	Survivors N = 35 (71) <sup>1</sup>	Non survivors N = 14 (29) <sup>1</sup>	<i>p</i> -value <sup>2</sup>
Reasons for ICU readmission				
Acute respiratory failure	35 (71)	22 (63)	13 (93)	0.042
Infectious disease	28 (57)	21 (60)	7 (50)	0.52
• Pneumonia	22 (45)	15 (43)	7 (50)	0.65
• Pleuropneumonia	3 (6)	3 (9)	0 (0)	0.55
• Bacteraemia	2 (4)	2 (6)	0 (0)	1
• Mediastinitis	1 (2)	1 (3)	0 (0)	1
• <i>Pseudomonas aeruginosa</i> infection	14 (29)	10 (29)	4 (29)	1
• <i>Stenotrophomonas maltophilia</i> infection	1 (2)	1 (3)	0 (0)	1
Airway complication	11 (22)	5 (14)	6 (43)	0.055
Acute antibody-mediated rejection	4 (8)	4 (11)	0 (0)	0.31
Cardiovascular complication	2 (4)	1 (3)	1 (7)	0.49
• Acute coronary disease	1 (2)	1 (3)	0 (0)	1
• Limb acute ischaemia	1 (2)	0 (0)	1 (7)	0.29
Ketoacidosis	1 (2)	1 (3)	0 (0)	1
Characteristics of ICU stay				
SOFA score on admission	6 4-8	6 [4-8]	7 [4-9]	0.75
• PaO <sub>2</sub> /FiO <sub>2</sub> < 200 on admission	20 (42)	15 (44)	5 (36)	0.59
• Thrombocytopaenia on admission	4 (9)	2 (6)	2 (15)	0.30
• MAP < 65 mmHg on admission				
• Glasgow coma scale < 14 on admission				

Delay of ICU readmission, days	17 (35)	12 (35)	5 (36)	1
	13 (29)	8 (25)	5 (38)	0.47
	108 [33-161]	76 [33-160]	136 [50-173]	0.52
Need for catecholamines	20 (41)	7 (20)	13 (93)	< 0.001
NIV	10 (20)	7 (20)	3 (21)	1
High-flow oxygen therapy	6 (12)	5 (14)	1 (7)	0.66
Need for MV	25 (52)	12 (35)	13 (93)	< 0.001
AKI	25 (52)	15 (43)	10 (77)	0.036
Need for RRT	8 (16)	4 (11)	4 (29)	0.20
Need for ECMO	6 (12)	1 (3)	5 (36)	0.005
Decision to withdraw or withhold treatment	8 (16)	3 (9)	5 (36)	0.033

---

Continuous variables are expressed as median and interquartile range (IQR) and were compared using the Mann-Whitney U test. Categorical variables are expressed as n (%) and were compared with Fisher's exact test. (ICU: intensive care unit; SOFA: sequential organ failure assessment; MAP: mean arterial pressure; NIV: non-invasive ventilation ; MV : mechanical ventilation ; AKI : acute kidney injury; RRT : renal replacement therapy; ECMO : extracorporeal membrane oxygenation)

<sup>1</sup> n (%); Median [IQR]

<sup>2</sup> Fisher's exact test; Pearson's Chi-square test; Wilcoxon rank sum test

---

**Table 3:** Characteristics and outcome of readmitted patients depending on hospital discharge after LT (*ICU: intensive care unit; NIV: non-invasive ventilation; MV: mechanical ventilation; AKI: acute kidney injury; RRT: renal replacement therapy; ECMO: extracorporeal membrane oxygenation*)

	ICU readmission after hospital discharge N = 19 (39) <sup>1</sup>	ICU readmission during initial hospitalisation N = 30 (61) <sup>1</sup>	p-value <sup>2</sup>
Risks factors for ICU readmission			
High dose of catecholamines	8 (42)	17 (57)	0.39
Duration of ICU stay	15 [9-21]	23 [13-35]	0.035
Reasons for ICU readmission			
Respiratory failure	15 (79)	20 (67)	0.35
Infectious disease	15 (79)	13 (43)	0.014
• Pneumonia	11 (58)	11 (37)	0.15
• Pleuropneumonia	2 (11)	1 (3)	0.55
• Bacteraemia	1 (5)	1 (3)	1
• Mediastinitis	1 (5)	0 (0)	0.39
• <i>Pseudomonas aeruginosa</i> infection	8 (42)	6 (20)	0.095
• <i>Stenotrophomonas maltophilia</i> infection	1 (5)	0 (0)	0.39
Airway complication	1 (5)	9 (30)	0.066
Acute antibody-mediated rejection	1 (5)	3 (10)	1
Cardiovascular complication	0 (0)	2 (6)	0.52
• Acute coronary disease	0 (0)	1 (3)	1
• Acute limb ischaemia	0 (0)	1 (3)	1
Ketoacidosis	1 (5)	0 (0)	0.39
Characteristics of ICU stay			



Medical ICU	9 (47)	5 (17)	0.020
SOFA score on admission	6 [4-9]	6 [3-8]	0.75
<ul style="list-style-type: none"> <li>• PaO<sub>2</sub>/FiO<sub>2</sub> &lt; 200 on admission</li> <li>• Thrombocytopenia on admission</li> <li>• MAP &lt; 65 mmHg on admission</li> <li>• Glasgow coma scale &lt; 14</li> </ul>	6 (32)	14 (48)	0.25
	2 (11)	2 (7)	0.63
	7 (37)	10 (34)	0.87
	6 (35)	7 (25)	0.46
Delay of readmission, days	168 [127-242]	42 [23-128]	< 0.001
Need for catecholamines	6 (32)	14 (47)	0.30
NIV	5 (26)	5 (17)	0.48
High-flow oxygen therapy	2 (11)	4 (13)	1
Need for MV	8 (42)	17 (59)	0.26
AKI	11 (58)	14 (48)	0.51
Need for RRT	2(11)	6 (20)	0.46
Need for ECMO	0 (0)	6 (20)	0.069
Decision to withdraw or withhold treatment	3 (16)	5 (17)	1
<b>Outcome</b>			
Death at one year	4 (21)	10 (33)	0.35

Continuous variables are expressed as median and interquartile range (IQR) and were compared using the Mann-Whitney U test. Categorical variables are expressed as n (%) and were compared with Fisher's exact test. (ICU : intensive care unit; SOFA: sequential organ failure assessment; MAP: mean arterial pressure; NIV : non-invasive ventilation ; MV : mechanical ventilation ; AKI : acute kidney injury; RRT : renal replacement therapy; ECMO : extracorporeal membrane oxygenation)

<sup>1</sup> n (%); Median [IQR]

<sup>2</sup> Pearson's Chi-square test; Fisher's exact test; Wilcoxon rank sum test


**Table 4:** Risk factors for death at one year, multivariate analysis

	OR <sup>1</sup>	95% CI <sup>1</sup>	<i>p</i>
Male gender	5.56	1.43-37.2	0.030
ECMO during surgery	1.72	0.47-8.25	0.4
Norepinephrine or epinephrine administration > 0.5 µg/kg/min during surgery	1.45	0.49-4.25	0.5
SAPS II score on ICU admission	1.01	0.97-1.04	0.6
ICU readmission in the first year after LT	4.32	1.50-13.8	0.009


ECMO: Extra Corporeal Membrane Oxygenation, SAPS II: Simplified Acute Physiology Score II, ICU: Intensive Care Unit, LT: Lung Transplantation

<sup>1</sup>OR = Odds Ratio, CI = Confidence Interval


**Figure 1:** Flow chart of the study



**Figure 2:** Delay for ICU readmissions during the first year after LT



**Figure 3:** One-year survival depending on ICU readmission during the first year after LT



## References:

1. Chambers DC, Cherikh WS, Harhay MO, Hayes D, Hsich E, Khush KK, et al. The International Thoracic Organ Transplant Registry of the International Society for Heart and Lung Transplantation: Thirty-sixth adult lung and heart-lung transplantation Report-2019; Focus theme: Donor and recipient size match. *J Heart Lung Transplant Off Publ Int Soc Heart Transplant*. 2019 Oct;38(10):1042–55.
2. Vigneswaran WT, Helenowski M, Bhorade SM, Lamounier F, Alex C, Garrity ER. Early readmission is a predictor of overall survival following isolated lung transplantation. *Int Surg*. 2010 Dec;95(4):299–304.
3. Pietrantonio C, Minai OA, Yu NC, Maurer JR, Haug MT, Mehta AC, et al. Respiratory failure and sepsis are the major causes of ICU admissions and mortality in survivors of lung transplants. *Chest*. 2003 Feb;123(2):504–9.
4. Banga A, Sahoo D, Lane CR, Mehta AC, Akindipe O, Budev MM, et al. Characteristics and outcomes of patients with lung transplantation requiring admission to the medical ICU. *Chest*. 2014 Sep;146(3):590–9.
5. Cohen J, Singer P, Raviv Y, Bakal I, Shitrit D, Lev S, et al. Outcome of lung transplant recipients requiring readmission to the intensive care unit. *J Heart Lung Transplant Off Publ Int Soc Heart Transplant*. 2011 Jan;30(1):54–8.
6. Mollberg NM, Howell E, Vanderhoff DI, Cheng A, Mulligan MS. Health care utilization and consequences of readmission in the first year after lung transplantation. *J Heart Lung Transplant Off Publ Int Soc Heart Transplant*. 2017 Apr;36(4):443–50.
7. González-Castro A, Suberviola B, Llorca J, González-Mansilla C, Ortiz-Melón F, Miñambres E. Prognosis factors in lung transplant recipients readmitted to the intensive care unit. *Transplant Proc*. 2007 Sep;39(7):2420–1.
8. Alrawashdeh M, Zomak R, Dew MA, Sereika S, Song MK, Pilewski JM, et al. Pattern and Predictors of Hospital Readmission During the First Year After Lung Transplantation. *Am J Transplant Off J Am Soc Transplant Am Soc Transpl Surg*. 2017 May;17(5):1325–33.
9. Osho AA, Castleberry AW, Yerokun BA, Mulvihill MS, Rucker J, Snyder LD, et al. Clinical predictors and outcome implications of early readmission in lung transplant recipients. *J Heart Lung Transplant Off Publ Int Soc Heart Transplant*. 2017 May;36(5):546–53.
10. Lushaj E, Julliard W, Akhter S, Levenson G, Maloney J, Cornwell RD, et al. Timing and Frequency of Unplanned Readmissions After Lung Transplantation Impact Long-Term Survival. *Ann Thorac Surg*. 2016 Aug;102(2):378–84.
11. Vigneswaran WT, Helenowski M, Bhorade SM, Lamounier F, Alex C, Garrity ER. Early readmission is a predictor of overall survival following isolated lung transplantation. *Int Surg*. 2010 Dec;95(4):299–304.

12. Hadjiliadis D, Steele MP, Govert JA, Davis RD, Palmer SM. Outcome of lung transplant patients admitted to the medical ICU. *Chest*. 2004 Mar;125(3):1040–5.
13. Tanaka S, Geneve C, Tebano G, Grall N, Piednoir P, Bronchard R, et al. Morbidity and mortality related to pneumonia and TRACHEOBRONCHITIS in ICU after lung transplantation. *BMC Pulm Med*. 2018 Mar 5;18(1):43.
14. Atchade E, Jean-Baptiste S, Houzé S, Chabut C, Massias L, Castier Y, et al. Fatal invasive aspergillosis caused by *Aspergillus niger* after bilateral lung transplantation. *Med Mycol Case Rep*. 2017 May 18;17:4–7.
15. Atchade E, Desmard M, Kantor E, Genève C, Tebano G, De Tymowski C, et al. Fungal Isolation in Respiratory Tract After Lung Transplantation: Epidemiology, Clinical Consequences, and Associated Factors. *Transplant Proc*. 2020 Feb;52(1):326–32.
16. Kao CC, Parulekar AD. Postoperative management of lung transplant recipients. *J Thorac Dis*. 2019 Sep;11(Suppl 14):S1782–8.
17. Snell GI, Yusef RD, Weill D, Strueber M, Garrity E, Reed A, et al. Report of the ISHLT Working Group on Primary Lung Graft Dysfunction, part I: Definition and grading-A 2016 Consensus Group statement of the International Society for Heart and Lung Transplantation. *J Heart Lung Transplant Off Publ Int Soc Heart Transplant*. 2017;36(10):1097–103.
18. Koeze J, Keus F, Dieperink W, van der Horst ICC, Zijlstra JG, van Meurs M. Incidence, timing and outcome of AKI in critically ill patients varies with the definition used and the addition of urine output criteria. *BMC Nephrol*. 2017 Feb 20;18(1):70.
19. Dezfouli AA, Najafizadeh K, Parsa T, Shadmehr MB, Dabir S, Mohammadi F, et al. Postlung transplant rehospitalization: a study of causes, health care burden, and outcomes. *Exp Clin Transplant Off J Middle East Soc Organ Transplant*. 2009 Sep;7(3):192–6.
20. Timmers TK, Verhofstad MHJ, Moons KGM, Leenen LPH. Patients' characteristics associated with readmission to a surgical intensive care unit. *Am J Crit Care Off Publ Am Assoc Crit-Care Nurses*. 2012 Nov;21(6):e120-128.
21. Ponzoni CR, Corrêa TD, Filho RR, Serpa Neto A, Assunção MSC, Pardini A, et al. Readmission to the Intensive Care Unit: Incidence, Risk Factors, Resource Use, and Outcomes. A Retrospective Cohort Study. *Ann Am Thorac Soc*. 2017 Aug;14(8):1312–9.
22. Lissauer ME, Diaz JJ, Narayan M, Shah PK, Hanna NN. Surgical intensive care unit admission variables predict subsequent readmission. *Am Surg*. 2013 Jun;79(6):583–8.
23. González-Castro A, Suberviola B, Llorca J, González-Mansilla C, Ortiz-Melón F, Miñambres E. Prognosis factors in lung transplant recipients readmitted to the intensive care unit. *Transplant Proc*. 2007 Sep;39(7):2420–1.